Literature DB >> 9013395

Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain. Short communication.

M Mogi1, M Harada, T Kondo, P Riederer, T Nagatsu.   

Abstract

The contents of interleukin (IL)-2 and basic fibroblast growth factor (bFGF) were measured in the brain (caudate nucleus, putamen, and cerebral cortex) from control and parkinsonian patients by highly sensitive enzyme-linked immunosorbent assay (ELISA). The concentrations of IL-2 in the brain were in the order of pg/mg protein, and the values were significantly higher in the caudate and putamen from parkinsonian patients than those from control patients. However, the levels of IL-2 in the cerebral cortex showed no significant difference between parkinsonian and control patients. In contrast to IL-2, the bFGF levels in the brain were high and in the order of ng/mg protein, and there was no significant difference in the caudate and putamen between parkinsonian and control patients. Although both IL-2 and bFGF may play important roles in dopaminergic neurons as neurotrophic factors, IL-2 but not bFGF may relate to the compensatory response in the nigrostriatal dopaminergic regions in parkinsonian brain during progress of neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9013395     DOI: 10.1007/BF01291792

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  22 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

2.  Stimulation of oligodendroglial proliferation and maturation by interleukin-2.

Authors:  E N Benveniste; J E Merrill
Journal:  Nature       Date:  1986 Jun 5-11       Impact factor: 49.962

3.  Bovine brain astrocytes express basic fibroblast growth factor, a neurotropic and angiogenic mitogen.

Authors:  N Ferrara; F Ousley; D Gospodarowicz
Journal:  Brain Res       Date:  1988-10-18       Impact factor: 3.252

4.  Transplanted adrenal chromaffin cells in rat brain reduce lesion-induced rotational behaviour.

Authors:  W J Freed; J M Morihisa; E Spoor; B J Hoffer; L Olson; A Seiger; R J Wyatt
Journal:  Nature       Date:  1981-07-23       Impact factor: 49.962

5.  Visualization of interleukin-2-like molecules in MPP(+)-lesioned rat brain.

Authors:  S M Liang; C M Liang; C C Chiueh
Journal:  Biochem Biophys Res Commun       Date:  1989-12-29       Impact factor: 3.575

6.  Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients.

Authors:  M Mogi; M Harada; T Kondo; P Riederer; H Inagaki; M Minami; T Nagatsu
Journal:  Neurosci Lett       Date:  1994-10-24       Impact factor: 3.046

7.  Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice.

Authors:  R E Heikkila; A Hess; R C Duvoisin
Journal:  Science       Date:  1984-06-29       Impact factor: 47.728

8.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.

Authors:  J W Langston; P Ballard; J W Tetrud; I Irwin
Journal:  Science       Date:  1983-02-25       Impact factor: 47.728

9.  Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients.

Authors:  M Mogi; M Harada; P Riederer; H Narabayashi; K Fujita; T Nagatsu
Journal:  Neurosci Lett       Date:  1994-01-03       Impact factor: 3.046

10.  Brain beta 2-microglobulin levels are elevated in the striatum in Parkinson's disease.

Authors:  M Mogi; M Harada; T Kondo; P Riederer; T Nagatsu
Journal:  J Neural Transm Park Dis Dement Sect       Date:  1995
View more
  16 in total

1.  Lymphocytes reduce nigrostriatal deficits in the 6-hydroxydopamine mouse model of Parkinson's disease.

Authors:  Chi Wang Ip; Sandra K Beck; Jens Volkmann
Journal:  J Neural Transm (Vienna)       Date:  2015-08-20       Impact factor: 3.575

Review 2.  Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance?

Authors:  Marina Romero-Ramos; Marianne von Euler Chelpin; Vanesa Sanchez-Guajardo
Journal:  Hum Vaccin Immunother       Date:  2014-03-26       Impact factor: 3.452

Review 3.  α-Synuclein in Parkinson's disease: causal or bystander?

Authors:  Peter Riederer; Daniela Berg; Nicolas Casadei; Fubo Cheng; Joseph Classen; Christian Dresel; Wolfgang Jost; Rejko Krüger; Thomas Müller; Heinz Reichmann; Olaf Rieß; Alexander Storch; Sabrina Strobel; Thilo van Eimeren; Hans-Ullrich Völker; Jürgen Winkler; Konstanze F Winklhofer; Ullrich Wüllner; Friederike Zunke; Camelia-Maria Monoranu
Journal:  J Neural Transm (Vienna)       Date:  2019-06-25       Impact factor: 3.575

Review 4.  Neurotrophic factors in neurodegenerative disorders : potential for therapy.

Authors:  Fabio Fumagalli; Raffaella Molteni; Francesca Calabrese; Paola Francesca Maj; Giorgio Racagni; Marco Andrea Riva
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

5.  Adjunctive therapy in Parkinson's disease: the role of rasagiline.

Authors:  Kathryn D Gaines; Vanessa K Hinson
Journal:  Neuropsychiatr Dis Treat       Date:  2012-07-02       Impact factor: 2.570

6.  The endotoxin-induced neuroinflammation model of Parkinson's disease.

Authors:  Kemal Ugur Tufekci; Sermin Genc; Kursad Genc
Journal:  Parkinsons Dis       Date:  2011-01-18

7.  CSF from Parkinson disease patients differentially affects cultured microglia and astrocytes.

Authors:  Mya C Schiess; Jennifer L Barnes; Timothy M Ellmore; Brian J Poindexter; Kha Dinh; Roger J Bick
Journal:  BMC Neurosci       Date:  2010-11-29       Impact factor: 3.288

8.  The degenerating substantia nigra as a susceptible region for gene transfer-mediated inflammation.

Authors:  Valeria Roca; Juan Cruz Casabona; Pablo Radice; Verónica Murta; Fernando Juan Pitossi
Journal:  Parkinsons Dis       Date:  2011-05-29

9.  The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration.

Authors:  Janelle Drouin-Ouellet; Claire Gibrat; Mélanie Bousquet; Frédéric Calon; Jasna Kriz; Francesca Cicchetti
Journal:  J Neuroinflammation       Date:  2011-10-11       Impact factor: 8.322

Review 10.  Genetic and Transcriptomic Profiles of Inflammation in Neurodegenerative Diseases: Alzheimer, Parkinson, Creutzfeldt-Jakob and Tauopathies.

Authors:  Irene López González; Paula Garcia-Esparcia; Franc Llorens; Isidre Ferrer
Journal:  Int J Mol Sci       Date:  2016-02-04       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.